British Heart Foundation Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK.
Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
ESC Heart Fail. 2024 Feb;11(1):65-77. doi: 10.1002/ehf2.14558. Epub 2023 Oct 9.
Red cell distribution width (RDW) is a strong prognostic marker in patients with heart failure (HF) and reduced ejection fraction and other conditions. However, very little is known about its prognostic significance in HF with preserved ejection fraction. We examined the relationship between RDW and outcomes and the effect of sacubitril/valsartan, compared with valsartan, on RDW and clinical outcomes in PARAGON-HF.
PARAGON-HF enrolled patients with a left ventricular ejection fraction of ≥45%, structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP). The primary endpoint was a composite of total HF hospitalizations and cardiovascular deaths. Median RDW at randomization was 14.1% (interquartile range 13.5-15.0%). Patients with higher RDW levels were more often men and had more comorbidity, a higher heart rate and NT-proBNP concentration, more advanced New York Heart Association class, and worse Kansas City Cardiomyopathy Questionnaire scores. There was a graded relationship between quartiles of RDW at randomization and the primary endpoint, with a significantly higher risk associated with increasing RDW, even after adjustment for NT-proBNP and other prognostic variables {Quartile 1, reference; Quartile 2, rate ratio 1.03 [95% confidence interval (CI) 0.83 to 1.28]; Quartile 3, 1.25 [1.01 to 1.54]; Quartile 4, 1.70 [1.39 to 2.08]}. This association was seen for each of the secondary outcomes, including cardiovascular and all-cause death. Compared with valsartan, sacubitril/valsartan reduced RDW at 48 weeks [mean change -0.09 (95% CI -0.15 to -0.02)]. The effect of sacubitril/valsartan vs. valsartan was not significantly modified by RDW levels at randomization.
RDW, a routinely available and inexpensive biomarker, provides incremental prognostic information when added to established predictors. Compared with valsartan, sacubitril/valsartan led to a small reduction in RDW.
红细胞分布宽度(RDW)是心力衰竭(HF)和射血分数降低以及其他情况下的一种强有力的预后标志物。然而,关于其在射血分数保留的 HF 中的预后意义知之甚少。我们研究了 RDW 与结局之间的关系,以及与缬沙坦相比,沙库巴曲缬沙坦对 PARAGON-HF 中的 RDW 和临床结局的影响。
PARAGON-HF 纳入了左心室射血分数≥45%、结构性心脏病和 N 末端 B 型利钠肽前体(NT-proBNP)升高的患者。主要终点是 HF 住院和心血管死亡的综合终点。随机分组时的 RDW 中位数为 14.1%(四分位间距 13.5-15.0%)。RDW 水平较高的患者更常见于男性,且合并症更多,心率和 NT-proBNP 浓度更高,纽约心脏协会(NYHA)心功能分级更高,堪萨斯城心肌病问卷(KCCQ)评分更差。RDW 在随机分组时的四分位数与主要终点之间存在分级关系,随着 RDW 的增加,风险显著增加,即使在调整了 NT-proBNP 和其他预后变量后也是如此{第 1 四分位数,参考值;第 2 四分位数,比率比 1.03(95%置信区间 0.83 至 1.28);第 3 四分位数,1.25(1.01 至 1.54);第 4 四分位数,1.70(1.39 至 2.08)}。这种关联见于次要结局的每一项,包括心血管和全因死亡。与缬沙坦相比,沙库巴曲缬沙坦可降低 48 周时的 RDW[平均变化-0.09(95%置信区间-0.15 至-0.02)]。与 RDW 在随机分组时的水平相比,沙库巴曲缬沙坦与缬沙坦的作用没有明显的改变。
RDW 是一种常规可用且价格低廉的生物标志物,当添加到已建立的预测因子中时,可提供额外的预后信息。与缬沙坦相比,沙库巴曲缬沙坦可使 RDW 略有降低。